Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, AstraZeneca Team on Gene Silencing Oncology Rx Studies

NEW YORK (GenomeWeb News) – Cenix BioScience said today it will work with the drug developer AstraZeneca in a tailored RNAi research collaboration aimed at advancing oncology drug targets.
 
Under the agreement, Cenix will combine its RNAi-based gene silencing technology with phenotypic analyses in cultured human cells. The research program will initially involve a high-throughput RNAi screen using an assay that the companies will design together to find and validate novel targets for cancer treatments.
 
Cenix said it would implement multi-parametric microscopy-based assays using Definiens’ Cellenger image analysis platform to provide datasets of cellular functions and the phenotypes of certain genes. These data can be used to discover and prioritize targets for drug development, Dresden, Germany-based Cenix said.
 
“We look forward to driving this relationship beyond the initial pilot through to multiple projects,” Cenix CEO and CSO Christophe Echeverri said in a statement.
 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.